Institutions / Elmind Capital, LP

Elmind Capital, LP

CIK 2052213 · Institution · as of Dec 31, 2025
Portfolio value
$338.85M
Positions
34
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 34 →
CompanyClassValueShares% of portfolio
Cogent Biosciences, Inc.$41.58M1,170,74012.3%
Syndax Pharmaceuticals Inc$38.97M1,855,00011.5%
Viridian Therapeutics, Inc.$26.72M858,6317.9%
Vera Therapeutics, Inc.$24.43M482,5007.2%
Celldex Therapeutics, Inc.$23.49M865,0006.9%
CG Oncology, Inc.$20.45M492,5006.0%
Biocryst Pharmaceuticals Inc$16.77M2,150,0004.9%
Vaxcyte, Inc.$13.45M291,5004.0%
Beam Therapeutics Inc.$13.20M476,3383.9%
Pharvaris N.V.$13.20M475,7503.9%
KalVista Pharmaceuticals Inc$12.94M801,3003.8%
Dynavax Technologies Corp$10.46M679,9003.1%
Tyra Biosciences, Inc.$9.20M350,0002.7%
Nurix Therapeutics, Inc.$8.73M460,0002.6%
Wave Life Sciences Ltd$7.61M447,8462.2%
MBX Biosciences, Inc.MBXCommon Stock$6.65M211,0002.0%
Krystal Biotech, Inc.$5.42M22,0001.6%
United Therapeutics Corp$5.36M11,0001.6%
BioMarin Pharmaceutical Inc$4.87M82,0001.4%
Relay Therapeutics, Inc.$4.54M536,9461.3%
Travere Therapeutics, Inc.$4.20M110,0001.2%
Protagonist Therapeutics Inc$3.32M38,0001.0%
Cullinan Therapeutics, Inc.$3.21M310,0000.9%
Liquidia CorpLQDACommon Stock$3.10M90,0000.9%
CytomX Therapeutics, Inc.$2.98M700,0000.9%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.